Pharsight

1. List of Givlaari drug patents

Application	Filing Date	Opposition Party	Legal Status
EP06025389A	2017-12-15	Silence Therapeutics GmbH	Revoked
EP10011217A	2017-04-13	Silence Therapeutics GmbH	Opposition rejected
EP02702247A	2010-12-10	Silence Therapeutics AG	Revoked
EP02702247A	2010-12-10	Sirna Therapeutics	Revoked
EP05002454A	2009-09-24	Silence Therapeutics AG	Granted and Under Opposition
EP05002454A	2009-09-24	ROQUES, Sarah Elizabeth	Granted and Under Opposition
EP05002454A	2009-09-23	PFIZER LIMITED	Granted and Under Opposition
EP05002454A	2009-09-23	Sanofi-Aventis Deutschland GmbH	Granted and Under Opposition
EP05002454A	2009-09-21	Sirna Therapeutics	Granted and Under Opposition
EP02710786A	2007-02-28	Sirna Therapeutics	Opposition rejected
EP02003683A	2006-03-08	atugen AG	Patent maintained as amended
EP02003683A	2006-03-08	Abbott Laboratories	Patent maintained as amended
EP02003683A	2006-03-07	Sirna Therapeutics, Inc.	Patent maintained as amended
EP02003683A	2006-03-07	Quark Biotech, Inc.	Patent maintained as amended
EP00910510A	2003-05-28	atugen AG	Revoked
EP00910510A	2003-05-28	Aventis Pharma Deutschland GmbH	Revoked
EP00910510A	2003-05-28	Grund, Martin, Dr.	Revoked
EP00910510A	2003-05-28	JANSSEN PHARMACEUTICA N.V.	Revoked
EP00910510A	2003-05-28	AstraZeneca AB	Revoked
EP00910510A	2003-05-28	Novartis AG	Revoked
EP00910510A	2003-05-28	Isis Pharmaceuticals, Inc.	Revoked
EP00910510A	2003-05-20	Sirna Therapeutics, Inc.	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US9150605	November, 2010	Decision	Charles Allerson et al

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546143	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of a target gene	Jan, 2022 (1 year, 4 months ago)
US9708610	ALNYLAM PHARMS INC	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Jan, 2024 (6 months from now)
US10273477	ALNYLAM PHARMS INC	Therapeutic compositions	Mar, 2024 (9 months from now)
US9708615	ALNYLAM PHARMS INC	Therapeutic compositions	Mar, 2024 (9 months from now)
US11530408	ALNYLAM PHARMS INC	Therapeutic compositions	May, 2024 (11 months from now)
US9150605	ALNYLAM PHARMS INC	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Aug, 2025 (2 years from now)
US10131907	ALNYLAM PHARMS INC	Glycoconjugates of RNA interference agents	Aug, 2028 (5 years from now)
US8828956	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (5 years from now)
US8106022	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (6 years from now)
US10125364	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Mar, 2033 (9 years from now)
US9133461	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	May, 2033 (9 years from now)
US11028392	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Oct, 2034 (11 years from now)
US10119143	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Oct, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Mar, 2033 (9 years from now)